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Abstract
Background: Pyrrolizidine alkaloids (PAs) are probably the most common plant constituents that
poison livestock, wildlife, and humans worldwide. Riddelliine is isolated from plants grown in the
western United States and is a prototype of genotoxic PAs. Riddelliine was used to investigate the
genotoxic effects of PAs via analysis of gene expression in the target tissue of rats in this study.
Previously we observed that the mutant frequency in the liver of rats gavaged with riddelliine was
3-fold higher than that in the control group. Molecular analysis of the mutants indicated that there
was a statistically significant difference between the mutational spectra from riddelliine-treated and
control rats.
Results: Riddelliine-induced gene expression profiles in livers of Big Blue transgenic rats were
determined. The female rats were gavaged with riddelliine at a dose of 1 mg/kg body weight 5 days
a week for 12 weeks. Rat whole genome microarray was used to perform genome-wide gene
expression studies. When a cutoff value of a two-fold change and a P-value less than 0.01 were used
as gene selection criteria, 919 genes were identified as differentially expressed in riddelliine-treated
rats compared to the control animals. By analysis with the Ingenuity Pathway Analysis Network,
we found that these significantly changed genes were mainly involved in cancer, cell death, tissue
development, cellular movement, tissue morphology, cell-to-cell signaling and interaction, and
cellular growth and proliferation. We further analyzed the genes involved in metabolism, injury of
endothelial cells, liver abnormalities, and cancer development in detail.
Conclusion:  The alterations in gene expression were directly related to the pathological
outcomes reported previously. These results provided further insight into the mechanisms
involved in toxicity and carcinogenesis after exposure to riddelliine, and permitted us to investigate
the interaction of gene products inside the signaling networks.
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Background
Pyrrolizidine alkaloids (PAs) are common constituents of
thousands of plant species around the world and PA-con-
taining plants are probably the most common poisonous
plants affecting livestock, wildlife, and humans. Thus, the
human health risk posed by exposure to PAs has been a
concern [1,2]. Out of more than 6000 plants, about 660
PAs and their N-oxide derivatives have been identified,
and at least half of them are genotoxic and many are tum-
origenic [1-4]. Riddelliine is a representative genotoxic
PA, and is present in plants growing in the rangelands of
the western United States [5-7]. These plants containing
riddelliine appear to enter the human food chain since
riddelliine residues have been detected in meat, milk, and
honey [7]. Riddelliine was nominated by the U.S. Food
and Drug Administration to the National Toxicology Pro-
gram (NTP) for genotoxicity and carcinogenicity testing
due to the potential for human exposure [5].
Riddelliine is a 12-membered macrocyclic diester PA with
an α, β-unsaturated double bond linked to the ester group
at the C-7 position of the necine base. Riddelliine is com-
pletely absorbed within 30 minutes after gavage dosing to
rodents and metabolized to the major metabolites, 6,7-
dihydro-1-hydroxymethyl-5H-pyrrolizine (DHP) and rid-
delliine N-oxide, by mammalian microsomes [8-10]. 32P-
Postlabeling-HPLC analysis has identified a set of DHP-
derived DNA adducts from rat and human liver micro-
somal metabolism of riddelliine in vitro [11] and in the
livers of rats treated in vivo [12]. A linear dose-dependent
formation of DHP-derived DNA adducts was observed in
riddelliine-treated rats [12,13]. Riddelliine is genotoxic
both in vitro and in vivo, inducing increases in sister chro-
matid exchange, chromosomal aberrations, unscheduled
DNA synthesis, and micronucleated erythrocyte frequen-
cies [6]. In the NTP carcinogenicity studies, riddelliine was
tumorigenic, causing liver tumors in male mice and both
sexes of rats, mononuclear cell leukemia in rats, and lung
neoplasms in female mice. Riddelliine induced a high
incidence of liver hemangiosarcomas (derived from
endothelial cells) and lower incidences of hepatocellular
carcinoma (HCC; derived from parenchymal cells) in rat
liver [5,6].
In our previous studies, we observed that riddelliine is
mutagenic in the liver of riddelliine-treated rats and that
the mutant frequencies (MFs) increased in a linear dose-
dependent manner. Riddelliine also produced a unique
mutational spectrum in the liver cII gene of Big Blue rats
with G:C → T:A transversions being the major type of
mutation [14]. Moreover, we found that the cII MF in liver
endothelial cells from riddelliine-treated rats was signifi-
cantly greater than the cII MF in endothelial cells from
control rats, suggesting that the relatively high mutagenic-
ity of riddelliine in rat liver endothelial cells may be par-
tially responsible for the tumorigenic specificity of this
agent [15]. It has been reported that riddelliine-treated
mice and rats have higher and more persistent DNA
adduct levels in liver endothelial cells than in parenchy-
mal cells [9]. The sensitivity of tissues and cell types to the
mutagenicity of carcinogens may be an important factor
in the tissue- and cell-specificity of tumorigenesis.
Microarray technology has a profound impact on gene
expression research because of its ability to examine the
expression of thousands of genes at a time. The differen-
tially expressed genes that are identified may be used to
develop potential biomarkers, elucidate molecular mech-
anisms, and create gene signatures that identify classes of
samples [16]. This technology, as one of the core technol-
ogies for pharmacogenomics and toxicogenomics, pro-
vides new insights into the effects of botanical chemicals
on biological systems and allow the macrodissection of
molecular events in botanical carcinogenesis [17,18].
Identification of unique gene expression patterns pro-
duced by botanical carcinogens may allow us to elucidate
the mechanisms of action. In this study, we treated rats
with a tumorigenic dose of riddelliine and conducted
microarray analysis of gene expression in the target tissue
liver. We found that the gene expression profiles were sig-
nificantly altered by riddelliine treatment, and many of
the differentially expressed genes were involved in metab-
olism, injury of liver endothelial cells, liver abnormalities,
and cancer development.
Results and discussion
Samples and DNA microarray data analysis
Liver samples used in this study were from a previous
report [14] in which female Big Blue rats were treated with
a carcinogenic dose (1 mg/kg, 5 days per week) of riddel-
liine for 12 weeks. The MF in the liver cII gene was about
3-fold higher than those in the untreated group and the
mutation spectra in the riddelliine-treated rats was signif-
icantly different from those in the control rats. In the
present study, gene expression profiles were determined
for the livers of control and riddelliine-treated rats using
the Applied Biosystems' Rat Genome Survey Microarray
which contains 26,857 verified rat genes. Because liver
tumors had not developed at the 12 week sacrifice time,
the gene expression changes reflected early events in the
carcinogenesis process.
After data normalized by Quantile normalization which is
recommended by the manufacturer, the intensities of the
whole rat gene data were analyzed by Principal Compo-
nents Analysis (PCA, Figure 1). A separation between con-
trol and riddelliine-treated groups was observed,
indicating that there was a riddelliine-treatment effect on
liver gene expression. PCA analysis also demonstrates that
sample #6 from the control group appears to be differentBMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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from the rest of the five sample arrays. Figure 2 shows the
pair-wise log2 intensity Pearson's correlation coefficients
for the 6 controls samples. The correlation coefficient
numbers containing samples #6 were lower than the oth-
ers. Therefore, this array was excluded from further data
analysis. Differentially expressed genes were identified
based on the criteria of fold-change greater than 2 (up and
down) and P-value less than 0.01 in comparison to the
control group (Figure 3). A total of 919 genes satisfied the
requirements, of which 429 genes were up-regulated and
490 genes were down-regulated in response to riddelliine
treatment. Among the differentially expressed genes, 781
were in the Ingenuity Pathway Analysis (version 3.0) data-
base, and 238 genes were mapped to the networks. Figure
4 shows the top 10 networks; each network was associated
with specific genes and involved in different functions.
The major relevant functions altered by riddelliine treat-
ment in rat liver are listed in Table 1. These functions
include cancer, cell death, tissue development, cell mor-
phology, cell-to-cell signaling and interaction, and cellu-
lar development. Because riddelliine treatments induce
relatively high DNA adduct formation, mutation induc-
tion, and tumor incidence in the liver endothelial cells
[6,9,14,15], we focused our analysis on genes involved in
carcinogenesis, mainly metabolism, injury of endothelial
cells, liver abnormalities, and cancer development using
Ingenuity Pathway Analysis.
Alteration of metabolizing genes
Since metabolic activation of riddelliine is required for
liver tumor induction [12,19], we investigated the gene
expression changes of drug metabolizing genes. Table 2
shows phases I, II, and III drug metabolizing genes whose
expression was significantly changed by riddelliine treat-
ment. Four phase 1 cytochrome P450 genes (Cyp2c12,
Cyp2e1, Cyp3a9, and Cyp26) were up-regulated. Phase 2
glutathione S-transferase (Gsta3) and phase 3 ATP-bind-
ing cassette transporters (Abcb1a and Abcc3) were also
up-regulated. In addition, there were many down-regu-
lated genes involved in these 3 subgroups (Table 2).
The hepatic cytochrome P450 (Cyp450) metabolizing
enzymes are involved in the oxidation of the necine base
of PAs with the Cyp3a's being the major enzymes catalyz-
ing the metabolism of retronecine-based PAs to form the
genotoxic pyrrolic ester DHP and N-oxide derivatives
[1,20]. In addition, Cyp3a enzyme inducers (e.g., dexam-
ethasone) and inhibitors (e.g., troleandomycin) cause
increased and decreased riddelliine-induced DHP forma-
tion, respectively [11,21]. We observed that Cyp3a9 gene
expression was increased 6-fold after riddelliine treatment
which is consistent with the metabolic activation findings
and suggests that Cyp3a9 is the major rat liver enzyme
involved in riddelliine's metabolic activation. In human
liver, it has been shown that Cyp3a4, which is equivalent
to rat Cyp3a9, catalyzes the bioactivation of PAs [20]. Our
finding of increase expression of Cyp2e1 is consistent
with data from Gordon et al. who demonstrated that ret-
rorsine (another of the PAs) caused increased expression
of hepatic Cyp2e1 in rats [22]. The observation that the
expression of many P450 genes were down-regulated may
be related to the finding that many herbal/dietary consti-
tutes form reactive intermediates capable of irreversibly
inhibiting some Cyp450 enzymes [23]. The down-regu-
lated P450 genes in this study may also contribute to
decreased formation of N-oxide derivatives, the detoxifi-
cation pathway. Thus, the biological relations of these
genes related to riddelliine toxicities warrant further inves-
tigations.
The glutathione pathway plays a critical role in the detoxi-
fication of many drugs and xenobiotics. However, there is
a lack of information on the types and isozymes of glu-
tathione  S-transferases (GST) that mediate glutathione
conjugation of different PAs [1]. In this study, we
observed that Gsta3 was increased 11-fold and Gstm1 and
Gstm2 were decreased about 2-fold after riddelliine treat-
ment (Table 2). These results imply that these particular
types of GSTs may therefore be involved in the conjuga-
tive detoxification of riddelliine electrophiles and play an
essential role in the cellular oxidative defense mecha-
Principal component analysis of gene expression profiles  from livers of control and riddelliine-treated rats Figure 1
Principal component analysis of gene expression pro-
files from livers of control and riddelliine-treated 
rats. No specific cut off was applied and the intensity of 
whole rat genome data was used. The blue and red dots indi-
cate control and riddelliine-treated samples, respectively.
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nisms. In addition, there were four ATP binding cassette
transporter genes altered (2 up-regulated and 2 down-reg-
ulated) (Table 2). These phase III transporters, localized
to the cell membrane, play key physiological roles in drug
availability, metabolism and toxicity resulting in protec-
tion of cells and tissues against xenobiotics [24].
Injury of liver endothelial cells
Riddelliine treatments induce relatively higher DNA
adduct formation, mutation induction, and tumor inci-
dence in the liver endothelial cell than in liver parenchy-
mal cells [6,9,15]. In this study, the gene expression
changes of a number of genes involved in the injury of
liver endothelial cell were detected (Table 3). They were
The pair-wise log2 intensity correlations within six samples of control group Figure 2
The pair-wise log2 intensity correlations within six samples of control group. No specific cut off was applied and the 
intensity of whole rat genome data was used. "L_CTR" means liver control, and R values are shown.
0.9694 0.9718 0.9696 0.9600 0.9692
0.9699 0.9718 0.9702 0.9603 0.9694
0.9718 0.9715 0.9735 0.9616 0.9718
0.9696 0.9702 0.9735 0.9612 0.9678
0.9600 0.9603 0.9616 0.9612 0.9591
0.9699 0.9715 0.9678 0.9591 0.9692
0.9694 0.9718 0.9696 0.9600 0.9692
0.9699 0.9718 0.9702 0.9603 0.9694
0.9718 0.9715 0.9735 0.9616 0.9718
0.9696 0.9702 0.9735 0.9612 0.9678
0.9600 0.9603 0.9616 0.9612 0.9591
0.9699 0.9715 0.9678 0.9591 0.9692BMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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mainly related to cell death (Adm, F3, Tnf, Tnfrsf6, and
Tnfsf10), cell movement (Edg5, Enpp2, and Il8ra), and
cell-to-cell signaling and interaction (Il11, Itga4, Itga6,
Lepr, and Slc7a5). We confirmed the up-regulation (2-4-
fold) of previously reported Hgf, Itga4, Tnfrsf6, and
Tnfsf10 [17], and also identified the novel up-regulated
genes of Lepr, Prkca, Slc7a5, and Src (Table 3).
Leptin (Lep) has been consistently associated with angio-
genesis and tumor growth. Leptin exerts its physiological
Volcano plots (log2 fold change vs. -log2 P-value) Figure 3
Volcano plots (log2 fold change vs. -log2 P-value). A gene was identified as significantly changed if the fold change was 
greater than 2 (up or down) and the P-value was less than 0.01 in comparison to the control group (red symbols). Each group 
consisted of 5 or 6 replicates.
490 down-regulated 429 up-regulated 490 down-regulated 429 up-regulatedBMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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action through its specific receptor (Lepr). Protein kinase
C alpha (Prkca) is a serine/threonine protein kinase that
has been implicated in the regulation of a variety of cellu-
lar functions in response to a diverse range of stimuli, and
has recently become a target for anti-cancer therapies [25].
It has been reported that solute carrier family 7 number 5
(Slc7a5) is translated into the heavy chain of the cell sur-
face antigen 4F2 and L-type amino acid transporter 1 and
is induced by many oxidation products [26]. Src encodes
non-receptor tyrosine kinases that are the intermediates of
information transfer, and control pathways as diverse as
cell growth, migration, death, and genome maintenance
[27]. The overexpression of these genes may be responsi-
ble to the detrimental effects of riddelliine.
Also, the decreased expression of some genes, such as
Adm, Edg5, and F11r, suggests a role in riddelliine-
induced toxicity. The G-protein-coupled receptors were
originally termed endothelial-cell-differentiation genes
(EDGs) that are upregulated during endothelial cell differ-
entiation [28]. Adrenomedullin (Adm) is a vasodilator
peptide having a wide range of biological actions such as
reduction of oxidative stress and inhibition of endothelial
cell apoptosis [29]. The F11 receptor (F11r) plays a critical
role in the function of endothelial cells and in platelet
adhesion to inflamed endothelium [30]. Thus, reduction
in the expression of these genes may result in less protec-
tion against oxidative stress leading to injury of liver
endothelial cells.
The pathway analysis of gene expressions for the liver of rats treated with riddelliine Figure 4
The pathway analysis of gene expressions for the liver of rats treated with riddelliine. The top 10 networks were 
selected by Ingenuity pathway analysis database.BMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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Genes involved in liver abnormalities
In our previous study, we determined MFs in the liver cII
gene of Big Blue transgenic rats treated with 0.1 to 1 mg/
kg riddelliine for 12 weeks, and observed increases of MF
in a linear dose-dependent manner [14]. The increase in
MF was consistent with dose-dependent DHP-derived
DNA adduct formation [12]. Chronic exposure to 1 mg/kg
of riddelliine resulted in the alteration of a number of
genes involved in liver injury and abnormalities (Table 4).
Significantly changed genes were divided into subsets
based on functionality, and categories included cell death
(e.g., Ahr, Igfbp1, Il15, and Prkcz), cellular growth and
proliferation (e.g., Il7, Prkca, and Tgfa), oxidative stress
(Mt1a, Nqo1, and Ren), and liver morphology (Igfbp2,
Mthfd2, Pparg, and Tgfa).
The decreased expressions of Mthfd2, Pparg, Tgfa, and Tnf
indicated that hepatic system development and function
were harmed by riddelliine exposure, whereas the ele-
vated Ahr, Igfbp1, Il15, Prkcz, Tnfrsf6, and Tnfsf10 were
responsible for the cell death. Riddelliine treatment also
resulted in 2- to 11-fold up-regulation of Mt1a, Nqo1, and
Ren, suggesting the induction of oxidative stress. The met-
allothioneins (e.g., Mt1a), a family of proteins with anti-
oxidant activity, are upregulated in response to zinc and
oxidative stress [31]. Nqo1 gene expression is coordi-
nately induced with other detoxifying enzyme genes in
response to xenobiotics, antioxidants, oxidants, heavy
metals, and radiations [32]. Renin (Ren) is involved in the
renin-angiotensin-aldosterone system (RAS) which plays
a major role in progressive liver fibrosis, and the blockade
Table 1: The major relevant functions altered by riddelliine treatment in liver
Function Category Significance Associated Genes
Tissue Development 2.59E-5 – 4.05E-2 64
Cell Morphology 3.35E-5 – 3.99E-2 64
Cancer 8.84E-5 – 3.99E-2 70
Cell Death 8.84E-5 – 3.99E-2 66
Cell-To-Cell Signaling and Interaction 5.51E-4 – 4.05E-2 58
Lipid Metabolism 7.31E-4 – 3.99E-2 44
Cellular Development 2.12E-3 – 3.56E-2 58
Cellular Growth and Proliferation 2.12E-3 – 3.99E-2 37
Cell Cycle 3.96E-3 – 4.04E-2 31
Cellular Movement 4.00E-3 – 3.89E-2 39
Table 2: Genes involved in drug metabolisms altered by riddelliine treatment in liver
Gene symbol Gene description Locus link ID Fold change P-value
Phase I metabolism
CYP2C cytochrome P450, family 2, subfamily c 29277 0.003 0.00000
CYP2C12 cytochrome P450, family 2, subfamily c 25011 41.89 0.00000
CYP2C13 cytochrome P450, family 2, subfamily c 171521 0.002 0.00000
CYP2C22 cytochrome P450, family 2, subfamily c 171518 0.37 0.00000
CYP2E1 cytochrome P450, family 2, subfamily e 25086 2.07 0.00001
CYP3A2 cytochrome P450, family 3, subfamily a 266682 0.002 0.00000
CYP3A9 cytochrome P450, family 3, subfamily a 171352 6.38 0.00000
CYP3A18 cytochrome P450, family 3, subfamily a 252931 0.06 0.00000
CYP4A12 cytochrome P450, family 4, subfamily a 266674 0.20 0.00000
CYP26 cytochrome P450, family 26 154985 11.82 0.00049
Phase II metabolism
GSTA3 glutathione S-transferase, alpha 3 14859 11.80 0.00001
GSTM1 glutathione S-transferase, mu 1 24423 0.40 0.00036
GSTM2 glutathione S-transferase, mu 2 24424 0.48 0.00005
Phase III metabolism
ABCB1A ATP-binging cassette, subfamily b (MDR/TAP) 170913 2.65 0.00001
ABCC3 ATP-binging cassette, subfamily c (CFTR/MRP) 140668 10.07 0.00004
ABCC8 ATP-binging cassette, subfamily c (CFTR/MRP) 25559 0.38 0.00001
ABCC9 ATP-binging cassette, subfamily c (CFTR/MRP) 25560 0.47 0.00013BMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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of the RAS could be effective in preventing fibrosis pro-
gression in chronic liver diseases [33].
Regulation of cancer development
The 2-year NTP carcinogenicity study showed that riddel-
liine induced liver tumors in rats and male mice, lung
tumors in female mice, and leukemia in rats, and that liver
tumors were the cause of death for the most of these ani-
mals [5,6]. In the present study, pathway and function
analysis indicated 70 genes involved in liver cancer devel-
opment (Figure 5), including 17 genes coding for proteins
located in nucleus, 18 genes coding for proteins in the
cytoplasm, 18 genes encoding plasma membrane pro-
teins, and 15 genes encoding proteins in the extracellular
space. These significantly up- and down-regulated genes
were also categorized into subgroups, including ligand-
dependent nuclear receptor (Ahr, Ar, and Pparg), tran-
scription regulator (Crem, Egr1, Egr3, Hdac11, Mllt7, and
Table 4: Genes involved in liver injury and abnormalities altered by riddelliine treatment
Gene Description Locus link ID Fold change P-value
* AHR aryl hydrocarbon receptor 25690 2.03 0.0030
* EDG5 endothelial differentiation, G-protein-coupled receptor, 5 29415 0.19 0.0000
* EGR1 early growth response 1 24330 2.13 0.0090
F7 coagulation factor VII 260320 2.22 0.0000
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 24446 2.46 0.0080
* IGFBP1 insulin-like growth factor binding protein 1 25685 3.42 0.0020
* IGFBP2 insulin-like growth factor binding protein 2 25662 15.53 0.00001
* IL11 interleukin 11 171040 2.38 0.0020
* IL15 interleukin 15 25670 2.00 0.00000
* IL7 interleukin 7 25647 0.25 0.0000
* MMP7 matrix metalloproteinase 7 (matrilysin, uterine) 25335 0.05 0.00006
* MT1A metallothionein 1A (functional) 24567 11.10 0.0030
MTHFD2 methylenetetrahydrofolate dehydrogenase 2, 17768 0.33 0.0060
* NQO1 NAD(P)H dehydrogenase, quinone 1 24314 2.48 0.0030
* PPARG peroxisome proliferative activated receptor, gamma 25664 0.17 0.00052
* PRKCA protein kinase C, alpha 24680 2.41 0.0000
* PRKCZ protein kinase C, zeta 25522 3.22 0.0020
REN renin 24715 4.48 0.0010
* TGFA transforming growth factor, alpha 24827 0.36 0.0000
* TNF tumor necrosis factor (TNF superfamily, member 2) 24835 0.05 0.0000
* TNFRSF6 Fas (TNF receptor superfamily, member 6) 246097 3.34 0.0010
* TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 246775 2.40 0.0020
* Genes also involved in cancer development.
Table 3: Genes involved in endothelial cells altered by riddelliine treatment in liver
Gene Description Locus link ID Fold change P-value
* ADM adrenomedullin 25026 0.11 0.0010
EDG5 endothelial differentiation, G-protein-coupled receptor, 5 29415 0.19 0.0000
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 84050 0.25 0.0000
F11R F11 receptor 50848 0.43 0.0000
* F3 coagulation factor III (thromboplastin, tissue factor) 25584 0.36 0.0040
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 24446 2.46 0.0080
* IL11 interleukin 11 171040 2.38 0.0020
* IL8RA interleukin 8 receptor, alpha 54258 2.40 0.0020
* ITGA4 integrin, alpha 4 311144 2.11 0.0020
* ITGA6 integrin, alpha 6 114517 0.35 0.0000
LEPR leptin receptor gene-related protein; leptin receptor 16847 3.09 0.0032
* PRKCA protein kinase C, alpha 24680 2.41 0.0000
SLC7A5 solute carrier family 7 member 5 50719 4.43 0.0040
* SRC v-src sarcoma viral oncogene homolog (avian) 83805 3.33 0.0050
* TNF tumor necrosis factor (TNF superfamily, member 2) 24835 0.05 0.0000
* TNFRSF6 Fas (TNF receptor superfamily, member 6) 246097 3.34 0.0010
* TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 246775 2.40 0.0020
* Genes also involved in cancer development.BMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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Rel), phosphatase (Cdc25b and Ppp2r1e), enzyme
(Akr1c3, Fut1, Mgat5, Nqo1, St6gal1, St8sia1, Fkbp5, and
Smox), kinase (Map2k6, Prkca, Prkcz, Src, Chek1, Fyn,
and Ntrk1), transmembrane receptor (F3, Fas, Prlr, and
Tnfrsf11a), G-protein coupled receptor (Edg5 and Il8ra),
growth factor (Ecgf1, Gdf15, and Tgfa), and cytokine (Il7,
Il11, Il15, Tnf, Tnfsf10, and Tnfsf13). Consequently, these
genes may affect multiple cellular events that contribute
to riddelliine-induced toxicological pathways.
The early gene expression changes in the carcinogenic
process may involve different genes or groups of genes,
depending on the carcinogen [34]. Riddelliine-induced
gene expression changes appeared to involve morphol-
ogy, cell death or apoptosis, growth, proliferation, and
binding-related genes. Among 70 genes, 11 genes were
also related to injury of liver endothelial cells (Table 3)
and 18 genes were related to liver injury and abnormali-
ties (Table 4). Riddelliine treatment increased the level of
Prlr, Ncr1, Igfbp2, Mt1A, Mt3, Ppp2r1b, and Timp3 about
250, 56, 15, 11, 8, 5, and 2-fold, respectively. It has been
reported that prolactin is involved in the pathogenesis of
liver cirrhosis and an accumulation of the prolactin recep-
tor (Prlr) is observed in hepatocytes damaged by cirrhosis
and fibrosis [35]. The surface density of the triggering
receptors (e.g., Ncr1 also called NKp46) responsible for
natural killer (NK) cell-mediated cytotoxicity determines
the ability of NK cells to kill susceptible target cells [36].
The dramatic increase in Ncr1 may, therefore, indicate an
increase in cells susceptible to cell-mediated toxicity. Insu-
lin-like growth factor-binding proteins (IGFBPs) are
important modulators of IGF actions, and overexpression
of Igfbp2 is observed in a variety of pathological condi-
tions. In addition, Igfbp2 is expressed in many malignant
tissues including liver, and Igfbp2 appears to be a suitable
marker for the evaluation of the serological status of HCC
patients [37]. Metallothioneins (MT) are a group of low-
molecular weight and cysteine rich intracellular proteins.
The expression and induction of these genes (e.g., Mt1a
and Mt3) have been associated with protection against
DNA damage, oxidative stress and apoptosis. A number of
studies have shown an increased expression of MT in var-
ious human tumors including hepatoma [38]. Ppp2r1b
has been implicated as a tumor suppressor gene, and
somatic alterations of Ppp2r1b have been detected in sev-
eral cancers. Most recently, Chou et al. reported that aber-
rant transcripts of Ppp2r1b might be associated with the
development of HCC [39]. Tumor-necrosis factor (TNF) is
a pleiotropic cytokine that triggers physiological and
pathological responses in several organs. TIMP3 is a cru-
cial innate negative regulator of TNF in both tissue home-
ostasis and tissue response to injury [40]. Thus, the
overexpression of these genes supports a critical role of
them in the toxicology of riddelliine.
Conclusion
The present study represents the first comprehensive in
vivo examination of the chronic transcriptional response
of the liver to riddelliine exposure. The available evidence
on the metabolism and target-tissue specificity for riddel-
liine's tumorigenesis suggests that active metabolites of
riddelliine interact with endothelial cells in the liver,
which causes cell toxicity, followed by compensatory pro-
liferation of DNA-damaged endothelial cells, 'fixation' of
the adducts into mutations in these cells, and eventual
development of hemangiosarcoma and HCC. We have
identified 919 genes in the livers of riddelliine-treated rats
that were differentially expressed and related to these
physiological and pathological outcomes. Relating the
gene expression changes to phenotypic anchors such as
metabolism, injury of liver endothelial cells, liver abnor-
malities, and cancer development, has helped in the inter-
pretation of these data. Although the significance of all of
the hundreds of gene expression changes is not fully
understood, the genome-wide global information
obtained herein will contribute to an improved under-
standing of the molecular alterations that occur after
exposure to riddelliine, and provide further insight into
the mechanisms involved in toxicity and carcinogenesis.
Materials and methods
Chemical and animals
Riddelliine (>97% pure by reversed-phase HPLC analysis)
was obtained from the NTP and dissolved in 0.9% sodium
chloride. Female Big Blue Fisher 344 transgenic rats were
obtained from Taconic Laboratories (Germantown, NY)
through purchase from Stratagene (La Jolla, CA). All ani-
mal procedures followed the recommendations of the
NCTR Institutional Animal Care and Use Committee for
the handling, maintenance, treatment, and sacrifice.
Riddelliine treatment
The treatment schedule was based on the preliminary
results from the NTP two-year chronic tumorigenicity bio-
assay [5]. Six-week-old Big Blue rats were treated with rid-
delliine at the dose of 1 mg/kg body weight by gavage five
times a week for 12 weeks. Vehicle control rats were gav-
aged with 0.9% sodium chloride. Six rats from treatment
and control groups were sacrificed one day after the last
treatment. The livers were isolated, frozen quickly in liq-
uid nitrogen, and stored at -80°C. Tumors had not devel-
oped at the 12 week sacrifice time so that gene expression
changes reflected early events in the carcinogenesis proc-
ess.
RNA isolation and quality control
Total RNA was isolated from liver tissues of 6 control and
6 riddelliine-treated rats using an RNeasy system (Qiagen,
Chatsworth, CA). The yield of the extracted RNA was
determined spectrophotometrically by measuring theBMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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optical density at 260 nm. The purity and quality of
extracted RNA were evaluated using the RNA 6000
LabChip and Agilent 2100 Bioanalyzer (Agilent Technol-
ogies, Palo Alto, CA). RNA samples with RNA integrity
numbers (RINs) greater than 8.5 were used for microarray
experiments performed using Applied Biosystems' Rat
The cellular compartments of liver proteins involved in cancer development encoded by genes whose expression was altered  by riddelliine treatment Figure 5
The cellular compartments of liver proteins involved in cancer development encoded by genes whose expres-
sion was altered by riddelliine treatment. The different categories of proteins are indicated by the shape of the symbols.BMC Bioinformatics 2007, 8(Suppl 7):S4 http://www.biomedcentral.com/1471-2105/8/S7/S4
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Genome Survey Microarray platform, which is a one chan-
nel microarray with chemiluminescence detection, and
contains 26,857 probes (60-mer) for the interrogation of
27,088 genes and 1592 controls that track system per-
formance through each experiment.
Preparation of digoxigenin labeled in vitro transcribed 
cRNA
All RNA targets were labeled using the Applied Biosystems
RT-IVT Labeling Kit Version 2.0. Briefly, 1.5 μg of total
RNA was reverse transcribed via 2 h incubation at 42°C
with ArrayScript RT enzyme (Ambion, Austin, TX) and
oligo dT-T7 primer. Double stranded cDNA was produced
following 2 h incubation with E. coli DNA polymerase
and RNase H at 16°C. Double-stranded cDNA was puri-
fied according to the RT-IVT kit protocol. In vitro tran-
scription was performed by incubation of the cDNA
product with T7 RNA polymerase, 0.75 mM Digoxigenin-
11-UTP (Roche Applied Science, Indianapolis, IN) and all
other NTPs for 9 h. Labeled cRNA was purified according
to the RT-IVT kit protocol and analyzed for quality and
quantity using standard UV spectrometry and the Bioana-
lyzer.
Hybridization of labeled cRNA to microarrays and 
microarray imaging
Digoxigenin labeled cRNA targets were hybridized to
Applied Biosystems Rat Whole Genome Survey Microar-
rays using the Applied Biosystems Chemiluminescent
Detection Kit. Briefly, 15 μg of labeled cRNA targets were
fragmented via incubation with fragmentation buffer pro-
vided in the kit for 30 min at 60°C. Fragmented targets
were hybridized to microarrays during a 16 h incubation
at 55°C with buffers and reagents from the Chemilumi-
nescent Detection Kit. Post-hybridization washes and
anti-Digoxigenin-Alkaline Phosphatase binding were per-
formed according to the protocol of the kit. Chemilumi-
nescence detection, image acquisition and analysis were
performed using Applied Biosystems Chemiluminescence
Detection Kit and Applied Biosystems 1700 Chemilumi-
nescent Microarray Analyzer following the manufacturer's
protocols. Images were auto-gridded and the chemilumi-
nescent signals were quantified, corrected for background,
and finally, spot- and spatially-normalized using the
Applied Biosystems 1700 Chemiluminescent Microarray
Analyzer software version 1.1.
Microarray data analysis
Raw microarray intensity data from the Applied Biosys-
tems' Rat Genome Survey Microarray were normalized
with Quantile normalization which is recommended by
the manufacturer. The normalized data were then input to
ArrayTrack, a software system developed by the FDA's
National Center for Toxicological Research for the man-
agement, analysis, visualization and interpretation of
microarray data [41]. Chemiluminescent signals from
1529 control probes that track system performance
through each experiment were not used in normalization.
The identification of differentially expressed genes based
on fold-change and t-tests cutoffs, and Principal Compo-
nent Analysis were conducted within ArrayTrack. Ingenu-
ity Pathway Analysis (Mountain View, CA) was used for
network and function analysis.
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